Stewart Bae, MD
Nephrology · Flushing, NYNPI 1205910999
Payments from drug & device makers
Across 334 payments — averaging $20.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$864
- Amarin Pharma, Inc.$684
- Amgen$644
- OPKO Pharmaceuticals, LLC$481
- Lilly USA, LLC$406
- plus $2K from 32 others
What the payments were for
- Food & beverage$6,37595%
- Education$3295%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 60 | $1,225 |
| Novo Nordisk | 48 | $864 |
| Amarin Pharma, Inc. | 34 | $684 |
| Amgen(2 entities) | 28 | $644 |
| OPKO Pharmaceuticals, LLC | 25 | $481 |
| Lilly USA, LLC | 20 | $406 |
| Vifor Pharma, Inc. | 10 | $212 |
| Bayer | 9 | $193 |
| Xeris Pharmaceuticals, Inc. | 12 | $182 |
| Gilead | 6 | $166 |
| Fresenius USA Marketing, Inc. | 7 | $135 |
| ANI Pharmaceuticals, Inc. | 7 | $135 |
| Novartis | 5 | $121 |
| Merck | 3 | $115 |
| Sanofi-aventis U.S. LLC | 5 | $105 |
| Otsuka America Pharmaceutical, Inc. | 6 | $99 |
| Akebia Therapeutics Inc | 4 | $84 |
| Abbott | 5 | $84 |
| Travere Therapeutics, Inc. | 4 | $78 |
| Exact Sciences | 3 | $72 |
| Nestle Healthcare Nutrition Inc. | 3 | $63 |
| AbbVie(2 entities) | 4 | $62 |
| Shire North American Group Inc | 3 | $60 |
| Fresenius USA Manufacturing, Inc. | 2 | $45 |
| Pfizer | 3 | $44 |
| Astellas Pharma US Inc | 2 | $44 |
| Ardelyx, Inc. | 2 | $41 |
| Sanofi | 2 | $39 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| Dexcom, Inc. | 1 | $26 |
| Boehringer Ingelheim | 1 | $26 |
| Calliditas Therapeutics US Inc. | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $18 |
| Mission Pharmacal Company | 1 | $18 |
| Mannkind Corporation | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$6,703 in reported general payments places this provider in the 75th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 149 | $187,972 |
| JanuviaSitagliptin Phosphate | 135 | $144,075 |
| VascepaIcosapent Ethyl | 263 | $133,908 |
| LokelmaSodium Zirconium Cyclosilicate | 68 | $97,167 |
| VelphoroSucroferric Oxyhydroxide | 21 | $71,137 |
| ProcritEpoetin Alfa | 18 | $49,347 |
| JardianceEmpagliflozin | 39 | $45,990 |
| Cinacalcet Hcl | 13 | $45,697 |
| OzempicSemaglutide | 37 | $44,220 |
| EliquisApixaban | 32 | $42,275 |
| ProliaDenosumab | 24 | $42,222 |
| RayaldeeCalcifediol | 21 | $25,696 |
| Diclofenac Epolamine | 22 | $14,127 |
| TradjentaLinagliptin | 15 | $13,711 |
| Diclofenac Sodium | 22 | $8,883 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,225 | $285,139217 claims |
| MerckJanuvia | $115 | $144,075135 claims |
| Fresenius USA Marketing, Inc.Velphoro | $135 | $71,13721 claims |
| Boehringer IngelheimJardiance, Tradjenta | $26 | $59,70154 claims |
| Novo NordiskOzempic | $864 | $44,22037 claims |
| PfizerEliquis | $44 | $42,27532 claims |
| AmgenProlia | $644 | $42,22224 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $481 | $25,69621 claims |
| Astellas Pharma US IncMyrbetriq | $44 | $8,03213 claims |
| AbbVieSynthroid | $62 | $1,19917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 935 nephrology providers in New York.
Other nephrology in Flushing
- Joji TokitaNew York$8.4M
- Krzysztof KirylukNew York$6.7M
- David BernardNew York$6M
- Andrew BombackNew York$3.4M
- Pietro CanettaNew York$3.2M
- Robert LynnBronx$2M
- Jodumutt BhatMaspeth$1.5M
- Gerald AppelNew York$1.5M
- David CharytanNew York$1.3M
- Frank CortazarAlbany$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.